COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
15/01/2026
The Science, Clinical Promise, & Market Outlook MELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on [...]
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
15/01/2026
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 [...]
Sienna Announces January Dividend
15/01/2026
MARKHAM, Ontario, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
15/01/2026
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. control There are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date [...]
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
15/01/2026
WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne [...]
HMNC Brain Health Presented Positive Phase 2b Data at American College of Neuropsychopharmacology Annual Meeting
15/01/2026
Company Shared Poster on Breakthrough Genetic Stratification Data from Positive Phase 2b OLIVE Trial Results for BH-200 MUNICH, Germany, Jan. 15, 2026 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage [...]
Extendicare Announces January 2026 Dividend of C$0.042 per Share
15/01/2026
MARKHAM, Ontario, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
ViroMissile Appoints Michael G. Wood as Chief Business Officer
15/01/2026
SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Michael G. [...]
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
15/01/2026
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM ( [...]
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
15/01/2026
Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive [...]
R1 Prior Authorization, Now Powered by the Phare OS, Accelerates Care, Reduces Costs and Improves Accuracy
15/01/2026
Combines AI-Powered Technology with R1 Experts to Set a New Standard for Clearance and Denial Rates CHICAGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, [...]
Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase
15/01/2026
Regulated manufacturing, hospital field trials, and regulatory filings now underway with Ebulent Medical in Shenzhen LAS VEGAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. ( OTCID: CBSC ) (“CBSC” [...]
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
15/01/2026
Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for advanced cancer [...]
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
15/01/2026
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report ® for 2025-26 [...]
Verano Announces Agreement to Upsize Revolving Credit Facility Commitment to $100,000,000 and Extend Maturity Date
15/01/2026
Amendment adds incremental $25,000,000 and extends maturity date from September 29, 2028 to February 28, 2029 CHICAGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or [...]
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
15/01/2026
This milestone marks significant progress in the first-in-human evaluation of AAVantgarde’s dual-AAV gene therapy designed to address the underlying cause of vision loss in patients with USH1B LONDON and MILAN, Jan. 15 [...]
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
15/01/2026
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first [...]
Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
15/01/2026
Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical Partner BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology [...]
Zelluna ASA: Approval and publication of prospectus
15/01/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]

Pages